Remicade infliximab: Phase II; marketed to treat rheumatoid arthritis (RA) and Crohn's disease

In a double-blind, placebo-controlled Phase II trial in 249 patients, 88% of patients treated with 5 mg/kg achieved a PASI 75 score compared to 6% of the placebo group after 10 weeks of therapy. Also,...